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Abstract
Chronic lead exposure induces hypertension and alters endothelial function. However, treatment with low lead
concentrations was not yet explored. We analyzed the effects of 7 day exposure to low lead concentrations on
endothelium-dependent responses. Wistar rats were treated with lead (1st dose 4 mg/100 g, subsequent dose 0.05 mg/
100 g, i.m. to cover daily loss) or vehicle; blood levels attained at the end of treatment were 9.98 mg/dL. Lead treatment had
the following effects: increase in systolic blood pressure (SBP); reduction of contractile response to phenylephrine (1 nM–
100 mM) of aortic rings; unaffected relaxation induced by acetylcholine (0.1 nM–300 mM) or sodium nitroprusside (0.01 nM–
0.3 mM). Endothelium removal, NG-nitro-L-arginine methyl ester (100 mM) and tetraethylammonium (2 mM) increased the
response to phenylephrine in treated rats more than in untreated rats. Aminoguanidine (50 mM) increased but losartan
(10 mM) and enalapril (10 mM) reduced the response to phenylephrine in treated rats. Lead treatment also increased aortic
Na+/K+-ATPase functional activity, plasma angiotensin-converting enzyme (ACE) activity, protein expression of the Na+/K+-
ATPase alpha-1 subunit, phosphorylated endothelial nitric oxide synthase (p-eNOS), and inducible nitric oxide synthase
(iNOS). Our results suggest that on initial stages of lead exposure, increased SBP is caused by the increase in plasma ACE
activity. This effect is accompanied by increased p-eNOS, iNOS protein expression and Na+/K+-ATPase functional activity.
These factors might be a compensatory mechanism to the increase in SBP.
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Introduction
Lead is considered an environmental pollutant of high risk to
public health [1,2].This metal is extensively used by the industrial
sector, thereby contributing to its wide environmental distribution.
Usually, plasma lead levels in humans result from exposure to
exogenous sources [3]. Occupational exposure occurs during the
manufacture of ammunition, batteries, solder, ceramic glazes,
plastics and sheet lead [4]. Lead affects the central nervous system
[3] and the renal system [5], and population studies have
demonstrated an association between lead exposure and kidney
disease [6,7]. Recently, more research has focused on the toxic
effects of lead on the cardiovascular system and its association with
hypertension in humans [8–10] and animals [11–13]. Several
mechanisms have been proposed to cause lead-induced hyperten-
sion, such as alterations in calcium exchangeability [14], central
sympathetic activity enhancement [15,12], increases in plasma
catecholamines [16], inhibition of the Na+/K+-ATPase [17],
direct activation of smooth muscle protein kinase C [18], increased
activity of the renin-angiotensin system [19] and endothelial
dysfunction [20,21].
Endothelial dysfunction is associated with hypertension and
with a concomitant increase in morbidity and mortality [22,23].
Vaziri et al. [21,22] showed that treatment with 100 ppm of lead
in drinking water for 12 weeks induces hypertension and
endothelial dysfunction in Sprague-Dawley rats. Several reports
have shown that the chronic lead treatment with 100 ppm in
drinking water increases vascular reactivity to phenylephrine in
aortic rings [24,25,13], although other authors have demonstrated
a decrease in the vascular reactivity to phenylephrine after lead
treatment [26]. It is still unclear whether this altered vascular
reactivity can contribute to lead-induced hypertension.
The Agency for Toxic Substances and Disease Registry
(ATSDR) recommends that the concentration of lead in the blood
is under 60 mg/dL in adults that experience occupational lead
exposure [3,27,28]; nevertheless, individuals with blood lead
concentrations between 31.4 mg/dL and 53.5 mg/dL showed an
increase in arterial pressure [6,9]. Recent experimental studies of
lead toxicity demonstrated a concentrations of lead in the blood
between 31.8 mg/dL and 58.7 mg/dL [29,30,13]; these concen-
trations are similar to those found in the population of workers
exposed to lead; however, little attention has been given to the
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effects of lead in the blood at concentrations below those found in
humans with occupational lead exposure and the effects during the
initial stages of lead exposure. Because of the lack of knowledge in
these areas, we developed an experimental model of lead exposure
in rats that produces blood concentrations below those found in
humans with occupational lead exposure. Thus, the aim of this
study was to investigate the effects of seven-day treatment with a
low concentration of lead acetate on the systolic blood pressure
(SBP) and vascular reactivity in aortic rings.
Materials and Methods
Animals and treatment
Male Wistar rats (260–300 g) were used for these studies. The
care and use of laboratory animals were in accordance with the
NIH guidelines, and all experiments were conducted in compli-
ance with the guidelines for biomedical research as stated by the
Brazilian Societies of Experimental Biology and were approved by
the Institutional Ethics Committee of the Health Science Center of
Vito´ria (CEUA-EMESCAM 004/2007). All rats had free access to
water and were fed rat chow ad libitum. Rats were divided into two
groups: control (vehicle-saline, i.m.) or treated with lead acetate for
seven days (1st dose: 4 mg/100 g, subsequent dose: 0.05 mg/100 g,
i.m. to cover daily loss). At the end of the treatment, rats were
anesthetized with pentobarbital (35 mg/kg, i.p.) and killed by
exsanguination. Thoracic aortas were carefully dissected out and
connective tissue was removed. For vascular reactivity experi-
ments, the aortas were divided into cylindrical segments 4 mm in
length. For analysis of protein expression, some arteries were
rapidly frozen in liquid nitrogen and stored at 280uC until
analyzed. Blood samples were collected in tubes without EDTA
and placed in ice and then centrifuged at 3,5006g for 15 min at
4uC. The resulting plasma was stored at 280uC until use to
determine ACE activity.
Blood pressure measurements
Indirect systolic blood pressure was measured at the beginning
and at the end of treatment using tail-cuff plethysmography (IITC
Life Science, Inc). Conscious rats were restrained for 5–10 min in
a warm and quiet room and conditioned to numerous cuff
inflation-deflation cycles by a trained operator. Systolic blood
pressure was measured, and the mean of three measurements was
recorded [13].
Blood lead level measurements
Blood lead level measurements were determined according to
the protocol developed by Koreckova´-Sysalova´ [31]. Lead
concentrations in samples of whole blood after 7 days of treatment
were measured in duplicate by atomic fluorescence spectrometry
(model: AAS5 EA with graphite furnace, Carl Zeiss, Germany) at
the Centre for Exact Sciences - Chemistry Department (Federal
University of Espirito Santo).
Vascular reactivity measurements
Aortic segments (4 mm in length) were mounted between two
parallel wires in 37uC organ baths containing Krebs-Henseleit
solution (KHS, in mM: 124 NaCl, 4.6 KCl, 2.5 CaCl2, 1.2
MgSO4, 1.2 KH2PO4, 0.01 EDTA, 23 NaHCO3) and gassed with
95% O2-5% CO2 (pH 7.4). Arterial segments were stretched to an
optimal resting tension of 1.0 g. Isometric tension was recorded
using a force displacement transducer (TSD125C, CA, USA)
connected to an acquisition system (MP100A, BIOPAC System,
Inc., Santa Barbara, USA).
After a 45 min equilibration period, all aortic rings were initially
exposed twice to 75 mM KCl. The first exposure checks their
functional integrity, and the second exposure assesses the maximal
tension developed. Afterwards, endothelial integrity was tested
with acetylcholine (10 mM) in segments previously contracted with
phenylephrine (1 mM). A relaxation equal to or greater than 90%
was considered demonstrative of the functional integrity of the
endothelium. After a 45 min washout, concentration-response
curves to phenylephrine were determined. Single curves were
performed in each segment. Effects of the nonspecific NOS
inhibitor NG-nitro-L-arginine methyl ester (L-NAME, 100 mM),
the inducible NO synthase (iNOS) inhibitor aminoguanidine
(50 mM), the potassium (K+) channel blocker tetraethylammonium
(TEA, 2 mM), the cyclooxygenase inhibitor indomethacin
(10 mM), the AT1 receptor blocker losartan (10 mM) and the
ACE inhibitor enalapril (10 mM) were investigated. These drugs
were added to the bath 30 min before performing the phenyl-
ephrine concentration-response curves.
The influence of the endothelium on the response to
phenylephrine in untreated and treated- lead rats was investigated
after its mechanical removal, which was performed by rubbing the
lumen with a needle. The absence of endothelium was confirmed
by the inability of 10 mM acetylcholine (ACh) to produce
relaxation.
In another set of experiments, after the 45 min equilibration
period, aortic rings from untreated and lead-treated rats were pre-
contracted with phenylephrine (1 mM), and concentration-re-
sponse curves to acetylcholine (0.1 nM–300 mM) or sodium
nitroprusside (0.01 nM–0.3 mM) were determined.
The functional activity of the Na+2/K+-ATPase in segments
from control and lead-treated rats was measured using K+-induced
relaxation, as described by Webb and Bohr [32] and modified by
Rossoni et al. [33]. After a 30-min equilibration period in normal
Krebs, preparations were incubated for 30 min in K+-free Krebs.
The vessels were subsequently pre-contracted with phenylephrine,
and once a plateau was attained, the concentration of KCl was
increased step-wise (1, 2, 5 and 10 mM), with each step lasting for
2.5 min. After these procedures, preparations were incubated with
100 mM ouabain for 30 min to inhibit sodium pump activity, and
the K+-induced relaxation curve was repeated.
Determination of angiotensin-converting enzyme (ACE)
activity
The effect of lead treatment on serum angiotensin-converting
enzyme (ACE) activity was determined according to the protocol
detailed by Oliveira et al. [34]. Briefly, serum (3 ml) was incubated
with 40 ml of assay buffer containing 5 mM Hip-His-Leu in 0.4 M
sodium borate buffer with 0.9 M NaCl, pH 8.3 for 15 min at
37uC. The reaction was stopped by the addition of 190 ml of
0.34 N NaOH. The product, His-Leu, was measured fluorome-
trically at an excitation wavelength 365-nm and an emission
wavelength of 495-nm using a fluoro-colorimeter (Synergy 2,
Biotek). Seventeen microliters of o-phthaldialdehyde (20 mg/ml) in
methanol was added. To correct for the intrinsic fluorescence of
the serum, time zero blanks (To) were prepared by adding serum
after NaOH. All assays were performed in triplicate.
Western blot analyses
Proteins from homogenized arteries (50 mg for eNOS, p-eNOS,
iNOS, AT1, AT2 receptors and 80 mg for Na
+/K+-ATPase alpha-
1 and 2 subunits) were separated by 10% SDS-PAGE. Proteins
were transferred to nitrocellulose membranes that were incubated
with mouse monoclonal antibodies for endothelial nitric oxide
synthase (eNOS), phosphorylated endothelial nitric oxide synthase
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(p-eNOS; 1:250; Transduction Laboratories, Lexington, UK),
inducible nitric oxide synthase (iNOS; 1:250; Transduction
Laboratories, Lexington, UK), Na+/K+-ATPase alpha-1 subunit
(1:1000; Millipore, San Francisco, USA) or Na+/2K+-ATPase
alpha-2 subunit (1:500; Millipore, San Francisco, USA) or rabbit
polyclonal antibodies for AT1 or AT2 (1:500; Biotechnology, Santa
Cruz, USA). After washing, membranes were incubated with anti-
mouse (1:5000; StressGen, Victoria, Canada) or anti-rabbit
(1:7000; StressGen, Victoria, Canada) antibodies conjugated to
horseradish peroxidase. After thorough washing, immunocom-
plexes were detected using an enhanced horseradish peroxidase/
chemiluminescence system (ECL Plus, Amersham International,
Little Chalfont, UK) and film (Hyperfilm ECL International).
Signals on the immunoblots were quantified with the National
Institutes of Health Image V1.56 software. The same membranes
were used to determine a-actin expression using a mouse
monoclonal antibody to a-actin (1:5000; Sigma, USA).
Statistical analyses
All values are expressed as mean 6 S.E.M. Contractile
responses were expressed as a percentage of the maximal response
induced by 75 mM KCl. Relaxation responses to ACh or NPS
were expressed as the percentage of relaxation of the maximal
contractile response. For each concentration-response curve, the
maximal effect (Rmax) and the concentration of agonist that
produced 50% of the maximal response (log EC50) were calculated
using non-linear regression analysis (GraphPad Prism, GraphPad
Software, Inc., San Diego, CA). The sensitivities of the agonists
were expressed as pD2 (2log EC50). To compare the effects of
endothelium denudation or L-NAME on the contractile responses
to phenylephrine, some results were expressed as differences in the
area under the concentration response curves (dAUC) for the
control and experimental groups. These values indicate whether
the magnitude of the effect of either endothelial denudation or L-
NAME is different in untreated or lead-treated rats. Relaxation
induced by K+ was expressed as a percentage of the tone
previously obtained with phenylephrine. The curves of relaxation
induced by K+ were constructed through the analysis of nonlinear
regression of the concentration-response curves.
For protein expression, data were expressed as the ratio between
signals on the immunoblot corresponding to the protein of interest
and a-actin. For protein expression of p-eNOS, data were
expressed as the ratio between p-eNOS/eNOS. Results are
expressed as mean 6 SEM of the number of rats indicated;
differences were analyzed using Student’s t-test or two-way
ANOVA followed by a Bonferroni test. P,0.05 was considered
significant.
Drugs and reagents
Lead acetate Pb(CH3COO)2, l-phenylephrine hydrochloride,
L-NAME, enalapril, indomethacin, acetylcholine chloride, sodium
pentobarbital, losartan, ouabain, sodium nitropusside, SOD,
aminoguanidine and tetraethylammonium were purchased from
Sigma-Aldrich (St. Louis, USA). Salts and reagents used were of
analytical grade from Sigma-Aldrich and Merck (Darmstadt,
Germany).
Results
No differences in body weight between the two groups were
observed before (untreated: 261.161.39 g, n = 40; lead-treated:
25960.98 g, n = 40; P.0.05) or after treatment (untreated:
305.562.88 g, n = 40; lead-treated: 310.162.68 g, n = 40;
P.0.05).
In rats exposed to seven-day lead treatment, the blood lead
concentration attained was 9.98 mg/dL61.70 mg/dL (n = 5). A
significant rise in systolic arterial blood pressure was observed
seven days after lead exposure (untreated: 12161.50 mmHg,
n = 12; lead treated: 13762.36 mmHg, n = 12, P,0.05).
Effects of lead treatment on vascular reactivity
Lead treatment did not affect the response to KCl (untreated:
3.4860.08 g, n = 39; lead-treated: 3.5260.09 g, n = 40; P.0.05),
but it decreased the contractile responses induced by phenyleph-
rine in rat aortas (Figure 1 A). It also decreased Rmax but not
sensibility to phenylephrine (Table 1).
The concentration-dependent relaxation induced by ACh did not
change in the treated group compared to the untreated group (Rmax
untreated: 98.9060.97, n = 8; Rmax lead-treated: 99.3760.50,
n = 9; pD2 untreated: 7.1360.32, n = 8; pD2 lead-treated:
7.5860.58, n = 9). Similarly, the response induced by NPS also
did not change in both groups (Rmax untreated: 10060.24, n = 8;
Rmax lead-treated: 10060.19, n = 9; pD2 untreated: 7.6360.33,
n = 8; pD2 lead-treated: 7.4360.13, n = 9) (Figures 1 B and C).
Effects of lead treatment on endothelial modulation of
vasoconstrictor responses
Both endothelium removal and incubation with the NOS
inhibitor L-NAME (100 mM) shifted the concentration-response
curves to the left after phenylephrine treatment in aortic segments
from either group, and this shift was greater in preparations from
lead-treated than untreated rats, as shown by the dAUC values
(Figures 2 A, B, C, D, E and F; Table 1). Lead treatment did not
modify eNOS protein expression in the aorta, although it
increased eNOS phosphorylation at Ser1177 (Figure 2 G).
Aminoguanidine (50 mM), a nonselective iNOS inhibitor,
increased the vasoconstrictor response induced by phenylephrine
in aortas from lead-treated rats, but it did not modify the responses
to phenylephrine in aortas from control rats (Figures 3 A and B,
Table 2). In addition, the protein expression of iNOS increased
after lead treatment (Figure 3 C).
Nitric oxide can open K+ channels [35] and contribute to a
reduction in contractile responses induced by phenylephrine in
aortas from lead-treated rats. TEA (2 mM), a K+ channel blocker,
potentiated the vasoconstrictor response induced by phenyleph-
rine in aortic segments from either group, but these effects were
greater in preparations from lead-treated than untreated rats, as
shown by the dAUC values (Figures 3 D, E and F; Table 2).
The cyclooxygenase inhibitor, indomethacin (10 mM), was used
to investigate the putative role of prostanoids on the decreased
response to phenylephrine in lead-treated rats. Indomethacin did
not alter the Rmax and pD2 values after phenylephrine treatment
in aortic segments from both groups (Table 1).
Effects of lead treatment on renin-angiotensin system
To investigate the involvement of the plasma renin-angiotensin
system in potentiating the effects of lead exposure, angiotensin
converting enzyme activity (ACE) was evaluated. Lead treatment
increased plasma ACE activity (Figure 4 A). There was a
significant correlation between systolic arterial blood pressure
and ACE activity in the plasma of lead-treated rats (r = 0.787,
P,0.05; Figure 4 B). These results reinforce the hypothesis that
the renin-angiotensin system is involved in the rise in arterial blood
pressure in lead-treated rats.
To investigate if the local renin-angiotensin system was involved in
the alterations of vascular reactivity after phenylephrine treatment
induced by lead, ACE and AT1 receptors were blocked with
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enalapril (10 mM) and losartan (10 mM), respectively. As show in
Figure 5 (A, B, C and D), both drugs reduced the vasoconstrictor
response induced by phenylephrine in aortas from lead-treated rats
but not in aortas from control rats (Table 2). This finding suggests
that lead affects the local renin-angiotensin system; however, western
blot analyses revealed similar levels of AT1 and AT2 protein
expression in the aortas from both groups (Figures 5 E and F).
Effects of lead treatment on Na+/K+-ATPase activity
We hypothesized that an increase in the Na+/K+-ATPase
activity might be causing the reduction in vascular reactivity after
phenylephrine treatment in the aortas from lead-treated rats. The
activity of the sodium pump, which was evaluated by the
potassium-induced relaxation curves before 100 mM ouabain
incubation, increased in aortic rings from treated rats (Figure 6).
Preincubation of intact segments with ouabain (100 mM) for
30 min in K+-free medium induced an increase in vascular tone in
the aortas from both groups, but the increase was smaller in the
last concentration of segments from lead-treated rats (Figure 6 A).
In addition to this finding, the protein expression of the Na+/K+-
ATPase alpha-1 subunit increased after lead treatment (Figure 6
B). However, the protein expression of the alpha-2 subunit of
Na+/K+-ATPase was similar in the aortas from untreated and
lead-treated rats (Figure 6 C).
Figure 1. The effects of seven-day exposure to lead acetate on the concentration-response curves to phenylephrine (A),
acetylcholine (B) and sodium nitroprusside (NSP; C) treatment in aortic rings. *P,0.05 by Student’s t-test. Number of animals used is
indicated in parentheses.
doi:10.1371/journal.pone.0017117.g001
Table 1. Parameters of maximal response (Rmax) and
sensitivity (pD2) of the concentration-response curves to
phenylephrine in the aortas from untreated and lead-treated
rats, before (E+) and after (E2) endothelial damage and after
NG-nitro-L-arginine methyl ester (L-NAME, 100 mM) and
indomethacin (10 mM) incubation.
Untreated Lead treated
Rmax pD2 Rmax pD2
Control 81.8064,46 6.5560,1 66.1564,66# 6.2960,06
E2 150. 467,32# 7.6560.14# 152.1610,43* 7.3760.10*
L-NAME 130.162,57# 7.6960.23# 148.963.22* 7.1260.05*
Indomethacin 85. 6468.71 6.6460,08 64.6165.67 6.3960.07
Results are expressed as mean6 SEM of the number of animals shown in Fig. 2;
Rmax, maximal effect (expressed as a percentage of the maximal response
induced by 75 mM KCl); pD2, 2log one-half Rmax; Control; E
2, endothelium
removal; L-NAME, N
G-nitro-L-arginine methyl ester; indomethacin. P,0.05 vs.
untreated control rats (#) and lead-treated control rats (*).
doi:10.1371/journal.pone.0017117.t001
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Discussion
The major findings from this study indicate that lead treatment
used to attain a blood lead content of 9.98 mg/dL is sufficient to
increase systolic arterial blood pressure and to decrease the
contractile responses induced by phenylephrine in the rat aorta.
This blood lead content is much lower than the reference value
(60 mg/dL) considered to be the upper limit of exposure in people
exposed to lead in their occupation [3,27,28]. We found that
elevated systolic arterial blood pressure is caused by increased
Figure 2. The effects of endothelium removal (E2) (A, B) and NG-nitro-L-arginine methyl ester (L-NAME, 100 mM) (D, E) on the
concentration-response curve for phenylephrine treatment in aortic rings from untreated (CT) and lead-treated rats (Pb+2). The inset
shows differences in area under the concentration-response curves (dAUC) in endothelium–denuded and intact segments (C) and in the presence
and absence of L-NAME (F). Densitometry analyses of western blots for endothelial nitric oxide synthase (eNOS) and phosphorylated endothelial nitric
oxide synthase (p-eNOS) protein expression in aortas from untreated (CT) and lead-treated rats (Pb+2) (G). Representative blots are also shown.
*P,0.05 by Student’s t-test. Number of animals used is indicated in parentheses.
doi:10.1371/journal.pone.0017117.g002
Figure 3. The effects of aminoguanidine (50 mM) (A, B) and TEA (2 mM) (D, E) on the concentration-response curves to
phenylephrine in endothelium-intact aortic segments from untreated (CT) and lead-treated rats (Pb+2). The inset shows differences in
dAUC in the presence and absence of TEA (F). Densitometry analyses of western blots for inducible nitric oxide synthase (iNOS) protein expression in
aortas from untreated (CT) and lead-treated rats (Pb+2) (C). Representative blots are shown. *P,0.05 by Student’s t-test. Number of animals used is
indicated in parentheses.
doi:10.1371/journal.pone.0017117.g003
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plasma ACE activity. The decrease in the contractile responses
after phenylephrine treatment in aortic rings from lead-treated rats
is probably due to the increase in negative endothelial modulation.
These responses might constitute a counterregulatory mechanism
that acts to oppose the increase in blood pressure produced by
lead.
The Centers for Disease Control and Prevention (CDC)
considers blood lead concentrations greater than or equal
10 mg/dL excessive for infants and children [36]. Blood lead
concentrations greater than or equal to 30 mg/dL are considered
elevated in adults; however, the Agency for Toxic Substances and
Disease Registry (ATSDR) recommends limiting blood lead
concentrations to 60 mg/dL in adults whose jobs expose them to
lead [3,27,28]. It has been reported that adults who experience
occupational lead exposure have an increase in blood lead
concentration (typically concentrations range from 30 to 60 mg/
dL) [6,37,9]. In South Korea, individuals who experience
occupational lead exposure have blood lead concentrations of
approximately 31.4 mg/dL [9]. That study indicated that lead
exposure acts continuously on systolic blood pressure, and
reductions in exposure may contribute to a decrease in blood
pressure. Several studies have supported the association between
high blood lead levels and hypertension [38,8,39]. In fact, previous
reports have suggested that chronic lead exposure at low levels
might contribute to hypertension. These studies showed the blood
lead concentrations in treated rats were between 31.8 mg/dL and
58.7 mg/dL [29,30,13]. In the present study, we treated rats with a
low dose of lead for seven days and attained a blood lead
concentration of 9.98 mg/dL. This concentration is lower than the
levels observed in individuals with occupational lead exposure;
nevertheless, this low concentration of lead increased systolic blood
pressure in the treated rats.
Lead may induce hypertension via multiple mechanisms, but
the pathogenesis is not entirely understood in the initial stages of
exposure. Previous studies have shown that lead increased the
synthesis and/or release of renin from the juxtaglomerular
apparatus [15], the production of aldosterone [40] and the activity
of plasma ACE [41,11]. In our study, increased systolic arterial
Table 2. Effects of aminoguanidine, TEA, losartan and enalapril on the vascular responses to phenylephrine (Rmax and pD2) in
aortas from untreated and lead-treated rats.
Untreated Lead treated
Rmax pD2 Rmax pD2
Control 82.0666,48 6.0260,15 60.3565,99# 6.1460.08
Aminoguanidine 86.9365.56 6.3660,19 83.7162,57* 6.2360.08
TEA 100.0463.70# 6.5060,11# 98.2965,30* 6.3060,08
Enalapril 79.1262.69 6.2160.13 48.9362.53* 6.2060.13
Losartan 79.7764.12 6.1960.05 35.1365.89* 5.9860.12
Results are expressed as mean 6 SEM of the number of animals shown in Figs. 3 and 5 ; Rmax, maximal effect (expressed as a percentage of the maximal response
induced by 75 mM KCl); pD2, 2log one-half Rmax; AG; aminoguanidine, TEA; tetraethylammonium, losartan, enalapril. P,0.05 vs. untreated control rats (
#) and lead-
treated control rats (*).
doi:10.1371/journal.pone.0017117.t002
Figure 4. Angiotensin converting enzyme (ACE) activity (nmol His-Leu/min) in plasma; correlation between systolic arterial blood
pressure and ACE activity (nmol His-Leu/min) in plasma of control and lead-treated rats (r = 0.787, P,0.05). *P,0.05 by Student’s
t-test. Number of animals used is indicated in parentheses.
doi:10.1371/journal.pone.0017117.g004
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pressure was accompanied by elevation of plasma ACE activity in
lead-treated rats; furthermore, there was a significant correlation
between systolic arterial blood pressure and ACE activity in the
plasma of lead-treated rats. Previous reports have shown that
elevation in systolic blood pressure after 2 weeks of lead treatment
(100 ppm lead acetate in drinking water) was accompanied by an
Figure 5. Effect of losartan (10 mM) (A, B) and enalapril (10 mM) (C, D) on the concentration-response curves to phenylephrine in
endothelium-intact aortic segments from untreated (CT) and lead-treated rats (Pb+2). Densitometry analyses of the western blots for
receptors AT1 (E) and AT2 (F) in aortas from untreated (CT) and lead-treated rats (Pb
+2). Representative blots are also shown.*P,0.05 by Student’s
t-test. Number of animals used is indicated in parentheses.
doi:10.1371/journal.pone.0017117.g005
Figure 6. Potassium-induced relaxation in aortic rings from untreated (CT) and lead-treated (Pb+2) rats previously incubated in a
K+-free medium and contracted with phenylephrine before and after incubation with 100 mM ouabain (A). Densitometry analyses of
the western blots for the alpha-1 subunit (B) and alpha-2 subunit (C) in aortas from untreated (CT) and lead-treated rats (Pb+2). Representative blots
are also shown. *P,0.05 (CT vs. Pb+2) by Student’s t-test or two-way ANOVA followed by a Bonferroni test. #P,0.05 (CT OUA vs. Pb+2 OUA) by two-
way ANOVA followed by a Bonferroni test. Number of animals used is indicated in parentheses.
doi:10.1371/journal.pone.0017117.g006
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increase in plasma ACE activity [19]. These findings suggest that
ACE activity might play a role in the initial stages of lead-induced
hypertension.
Previous studies have shown that alterations in vascular tone are
possibly involved in lead-induced hypertension [30,42]; however,
at low concentrations and in the initial stages of lead exposure,
changes in vascular reactivity have not yet been described. Several
reports have shown that chronic exposure to lead at low
concentrations induces vasoconstriction in the aorta [24,25,13].
Chronic exposure to lead (100 ppm for 10 months) also decreased
the contractile response induced by 5-HT in the aortas of lead-
treated rats [26]. These effects might be mediated by increased
production of reactive oxygen species [42], vasoconstrictor
prostanoids of the cyclooxygenase pathway [13] and pathomor-
phological changes in the vessels [26].
In this study, we observed a reduction in the reactivity to
phenylephrine in aortic rings after seven days of lead exposure.
The reduction in vascular reactivity to phenylephrine was
accompanied by a concomitant increase in the endothelial
modulation of such responses. To investigate NO modulation,
the NOS inhibitor, L-NAME, was used. We observed that L-
NAME increased the reactivity to phenylephrine in both
experimental groups; however, the magnitude of the effect of L-
NAME was higher in lead-treated rats. These results suggest that
lead increases NO bioavailability, thereby reducing reactivity to
phenylephrine in the aortic rings. In support of these data, we also
observed that a seven-day lead exposure increased eNOS
phosphorylation at Ser1177. This specific residue is the major
regulator of NO production [43,44]. Other investigators have also
indicated that high concentrations of lead increases the NO
bioavailability in rat tail arteries [45]; however, Karimi et al. [24]
showed that treatment with 100 ppm lead acetate for 28 days
reduces NO bioavailability in rat aortas. This study was performed
with chronic lead treatment, whereas our study was performed in
the initial stages of lead exposure. The results concerning the
effects of lead on NO production are controversial. Vaziri and
Ding et al. [46] showed that incubation with 1 ppm lead acetate
for 24 hours increases NO production in human coronary artery
endothelial cells; however, other reports have shown that
treatment with lead acetate (100 ppm in drinking water) for 12
weeks decreases [47,20,21,48] urine NO concentration. These
contradictory results are probably due to differences in the timing
and the form of lead treatment.
To investigate whether iNOS has a putative role mediating the
effects of lead treatment, aminoguanidine, an iNOS blocker, was
used. Aminoguanidine increased the effects of lead on the
contractile response to phenylephrine. Similarly, we found that
that lead exposure increased iNOS protein expression. These
results suggest that NO from iNOS also mediates the reduced
reactivity to phenylephrine induced by lead. Several reports have
also suggested that chronic exposure to lead increases the
expression of iNOS in the aorta [21,48], heart [48] and kidney
[29,48]. Although we demonstrated an increase in NO bioavail-
ability induced by lead, the relaxations induced by acetylcholine
and sodium nitroprusside were not altered after seven days of lead
exposure. These results indicate that after seven days, lead does
not seem to modify the release of NO stimulated by acetylcholine
or alter NO signaling pathways. In agreement with our findings,
Grizzo et al. [13] showed that lead did not change the induced
acetylcholine- and sodium nitroprusside-induced relaxations in
lead-treated rats.
The increased NO could open K+ channels and contribute to
increased negative modulation of the phenylephrine contraction.
We demonstrated that TEA, a K+ channel blocker, potentiated the
response to phenylephrine in aortic segments from either group,
but these effects were greater in preparations from lead-treated
than from untreated rats, as shown by dAUC values. These
findings suggest that NO might be activating K+ channels in
vascular smooth muscle cells, as previously reported [35,49].
Prostacyclin is another endothelium-derived vasodilator that
might be involved in negative endothelial modulation of aortic
rings from lead-treated rats. It has been shown that lead exposure
increases the activity of the cyclooxygenase pathways in aortic
rings [24,13] and in the tail vascular bed of rats [45]. In the
present study, indomethacin did not modify vascular reactivity to
phenylephrine in untreated and lead-treated rats. These findings
suggest that the cyclooxygenase pathway, at least in these initial
stages of exposure, is not involved in the decreased vascular
reactivity in aortas from lead-treated rats.
Seven days of lead exposure increased arterial systolic pressure,
even though vascular reactivity to phenylephrine decreased due to
an increased NO bioavailability in aortic rings. A previous study
showed that local angiotensin II stimulates the production of NO
in aortic endothelial cells [50]; therefore, we investigated whether
the local renin-angiotensin system might be involved in the
alterations of vascular reactivity to phenylephrine induced by lead.
We showed that losartan and enalapril decreased the contractile
response to phenylephrine in aortic rings from lead-treated rats,
which is in agreement with the increased plasma ACE activity
found in these rats. Despite the involvement of the local renin-
angiotensin system in this experimental model, which could induce
vasoconstriction, the vasodilatory effects of NO were more
significant and contributed to a reduction in the vascular reactivity
to phenylephrine. Western blot analyses showed similar levels of
AT1 and AT2 protein expression in the aortas from both groups.
These findings suggest that seven days of lead treatment was not
sufficient to produce alterations in the expression of these
receptors, even under conditions of increased plasma ACE
activity.
In this study, we showed that lead treatment induced the release
of endothelium-derived factors such as nitric oxide and angioten-
sin II; however, both nitric oxide and angiotensin II stimulate
Na+/K+-ATPase activity, which might reduce vascular tone
[51,52,53]. Therefore, we investigated the effects of lead treatment
on Na+/K+-ATPase functional activity, and we demonstrated that
lead increases Na+/K+-ATPase functional activity. We analyzed
this activity further by evaluating the expression of the alpha-1 and
alpha-2 subunits of the Na+/K+-ATPase. Western blot analyses
showed that the seven-day lead exposure increased the protein
expression of the Na+/K+-ATPase alpha-1 subunit; however, the
Na+/K+-ATPase alpha-2 subunit was present in similar levels in
aortas from untreated and lead-treated rats. Thus, the increased
NO bioavailability and angiotensin II production induced by lead
could be causing increased Na+/K+-ATPase functional activity.
In summary, seven day of lead treatment increased systolic
arterial blood pressure and reduced vascular reactivity to
phenylephrine in aortic segments from rats. The increased plasma
ACE activity could contribute to elevated systolic blood pressure in
lead-treated rats. In contrast, the decreased vascular reactivity due
to increased NO bioavailability might constitute a counter-
regulatory mechanism against the elevated systolic arterial
pressure observed in these animals, at least in the initial stages of
lead exposure. Lead treatment also increased p-eNOS and iNOS
protein expression. Presumably, the increased NO could open K+
channels and contribute to increased negative modulation of the
phenylephrine contraction. In addition, both angiotensin II and
NO bioavailability can stimulate Na+/K+-ATPase functional
activity by decreasing vascular reactivity. In conclusion, our
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results show that vascular changes and increased systolic blood
pressure occur in the initial stages of low-concentration lead
exposure, and thus, lead can be considered an important risk
factor for cardiovascular disease.
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